Martin J. Stoermer

Martin J. Stoermer

Auto-generated profile, based on publicly available information

Martin J. Stoermer

The University of Queensland

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2017 in Chemical Reviews
Verified
Journal Article
Closed access
DNDaniel S. Nielsen
Daniel S. Nielsen
NSNicholas E. Shepherd
Nicholas E. Shepherd
WXWeijun Xu
Weijun Xu
ALAndrew J. Lucke
Andrew J. Lucke
MSMartin J. Stoermer
Martin J. Stoermer
DFDavid P. Fairlie
David P. Fairlie

1 December 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DLDonmienne Leung
Donmienne Leung
KSKate Schroder
Kate Schroder
HWHelen White
Helen White
NFNing-Xia Fang
Ning-Xia Fang
MSMartin J. Stoermer
Martin J. Stoermer
DFDavid P. Fairlie
David P. Fairlie
Recombinant forms of the dengue 2 virus NS3 protease linked to a 40-residue co-factor, corresponding to part of NS2B, have been expressed in Escherichia coli and shown to be active against para-nitroanilide substrates comprising the P6-P1 residues of four substrate cleavage sequences. The enzyme is inactive alone or after the addition of a putative 13-residue co-factor peptide but is active when fused to the 40-residue co-factor, by either a cleavable or a noncleavable glycine linker. The NS4B/NS5 cleavage site was processed most readily, with optimal processing conditions being pH 9, I = 10 mm, 1 mmCHAPS, 20% glycerol. A longer 10-residue peptide corresponding to the NS2B/NS3 cleavage site (P6-P4′) was a poorer substrate than the hexapeptide (P6-P1) para-nitroanilide substrate under these conditions, suggesting that the prime side substrate residues did not contribute significantly to protease binding. We also report the first inhibitors of a co-factor-complexed, catalytically active flavivirus NS3 protease. Aprotinin was the only standard serine protease inhibitor to be active, whereas a number of peptide substrate analogues were found to be competitive inhibitors at micromolar concentrations.

1 February 2009 in Journal of Molecular Biology
Verified
Journal Article
Closed access
GRGautier Robin
Gautier Robin
KCKeith Chappell
Keith Chappell
MSMartin J. Stoermer
Martin J. Stoermer
SHShu-Hong Hu
Shu-Hong Hu
PYPaul Young
Paul Young
JMJennifer L. Martin
Jennifer L. Martin

1 February 2006 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
KAKatherine T. Andrews
Katherine T. Andrews
DFDavid P. Fairlie
David P. Fairlie
PMPraveen K. Madala
Praveen K. Madala
JRJohn Ray
John Ray
DWDavid M. Wyatt
David M. Wyatt
JMJames S. McCarthy
James S. McCarthy
Parasite resistance to antimalarial drugs is a serious threat to human health, and novel agents that act on enzymes essential for parasite metabolism, such as proteases, are attractive targets for drug development. Recent studies have shown that clinically utilized human immunodeficiency virus (HIV) protease inhibitors can inhibit the in vitro growth ofPlasmodium falciparumat or below concentrations found in human plasma after oral drug administration. The most potent in vitro antimalarial effects have been obtained for parasites treated with saquinavir, ritonavir, or lopinavir, findings confirmed in this study for a genetically distinctP. falciparumline (3D7). To investigate the potential in vivo activity of antiretroviral protease inhibitors (ARPIs) against malaria, we examined the effect of ARPI combinations in a murine model of malaria. In mice infected withPlasmodium chabaudiAS and treated orally with ritonavir-saquinavir or ritonavir-lopinavir, a delay in patency and a significant attenuation of parasitemia were observed. Using modeling and ligand docking studies we examined putative ligand binding sites of ARPIs in aspartyl proteases ofP. falciparum(plasmepsins II and IV) andP. chabaudi(plasmepsin) and found that these in silico analyses support the antimalarial activity hypothesized to be mediated through inhibition of these enzymes. In addition, in vitro enzyme assays demonstrated thatP. falciparumplasmepsins II and IV are both inhibited by the ARPIs saquinavir, ritonavir, and lopinavir. The combined results suggest that ARPIs have useful antimalarial activity that may be especially relevant in geographical regions where HIV andP. falciparuminfections are both endemic.

1 December 2009 in Antiviral Research
Verified
Journal Article
Closed access
TKThorsten Kampmann
Thorsten Kampmann
RYRagothaman Yennamalli
Ragothaman Yennamalli
PCPhillipa Campbell
Phillipa Campbell
MSMartin J. Stoermer
Martin J. Stoermer
DFDavid P. Fairlie
David P. Fairlie
PYPaul Young
Paul Young

1 November 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TNTessa A. Nall
Tessa A. Nall
KCKeith J. Chappell
Keith J. Chappell
MSMartin J. Stoermer
Martin J. Stoermer
NFNing-Xia Fang
Ning-Xia Fang
Joel TyndallJoel Tyndall
Joel Tyndall
DFDavid P. Fairlie
David P. Fairlie
West Nile Virus (WNV) is a mosquito-borne flavivirus with a rapidly expanding global distribution. Infection causes severe neurological disease and fatalities in both human and animal hosts. The West Nile viral protease (NS2B-NS3) is essential for post-translational processing in host-infected cells of a viral polypeptide precursor into structural and functional viral proteins, and its inhibition could represent a potential treatment for viral infections. This article describes the design, expression, and enzymatic characterization of a catalytically active recombinant WNV protease, consisting of a 40-residue component of cofactor NS2B tethered via a noncleavable nonapeptide (G4SG4) to the N-terminal 184 residues of NS3. A chromogenic assay using synthetic para-nitroanilide (pNA) hexapeptide substrates was used to identify optimal enzyme-processing conditions (pH 9.5, I < 0.1 m, 30% glycerol, 1 mm CHAPS), preferred substrate cleavage sites, and the first competitive inhibitor (Ac-FASGKR-H, IC50 ∼1 μm). A putative three-dimensional structure of WNV protease, created through homology modeling based on the crystal structures of Dengue-2 and Hepatitis C NS3 viral proteases, provides some valuable insights for structure-based design of potent and selective inhibitors of WNV protease.